Human studies on predictive biomarkers in pancreatic cancer
| Biomarkers | Target | Agent | Phase (number and characteristics of patients) | Outcomes | Ref. |
|---|---|---|---|---|---|
| KRAS | KRAS G12C mutation | AMG-510 (sotorasib) | I/II (38 patients with at least a previous therapy) | ORR: 21%, mPFS: 4 months, mOS: 6.9 months | [31] |
| MRTX849 (adagrasib) | I/II (21 patients with at least a previous therapy) | ORR: 33.3%, mPFS: 5.4 months, mOS: 8 months | [32] | ||
| BRCA | BRCA1/2 germline mutation | Olaparib | III placebo-controlled (154 patients, as maintenance therapy with stable or responding disease after 4 months of platinum) | mPFS: 7.4 months vs. 3.8 months (HR: 0.53), mOS: 19 months vs. 19.2 months (HR: 0.83) | [18] |
| BRCA1/2 and PALB2 germline and somatic mutation | Rucaparib | II single-arm (42 patients, as maintenance therapy with stable or responding disease after 4 months of platinum) | ORR: 41.6%, mPFS: 13.1 months, mOS: 23.5 months | [19] | |
| MMR genes | MSI-high | Pembrolizumab | II single-arm (22 patients, after progression on standard therapies) | ORR: 18.2%, mPFS: 2.1 months, mOS: 4 months | [60] |
MMR: mismatch repair; MSI-high: microsatellite instability high; mOS: median overall survival; ORR: objective response rate; Ref.: references; nc: not calculated; HR: hazard ratio; mPFS: median progression-free survival